14th Annual Advances in Oncology 2013

November 15-16, 2013
Sheraton Sacramento | Sacramento, CA

(The November 15th conference is held at the Cancer Center Auditorium
UC Davis Comprehensive Cancer Center)

CONFERENCE DIRECTORS

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

Primo N. Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

PRESENTED BY

UC DAVIS COMPREHENSIVE CANCER CENTER

SPONSORED BY:

THE MEDICAL EDUCATOR CONSORTIUM
The 14th Annual Advances in Oncology program will bring together academic and community oncologists for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. The program is designed to update physicians and other cancer healthcare providers on recent advances and new diagnostic and treatment modalities in hematologic, breast, lung, gastrointestinal, and genitourinary cancers. This course is intended for physicians and cancer health care providers, including medical, surgical and radiation oncologists, nurses, physician assistants, pharmacists and other interested health care professionals. The conference includes didactic sessions from national oncology leaders and case-based panel discussions involving academic and community oncologists.

EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, you should be able to:

1. Discuss advances in prognostic and predictive biomarkers and potential applications in therapeutic decision making.
2. Integrate targeted and traditional therapeutic modalities in the treatment of cancer.
3. Assess newly validated treatment options for patients with solid tumors or hematologic malignancies.
4. Apply data from recent clinical trials to determine the optimal course of therapy in defined patient populations, with emphasis on novel agents including mTOR inhibitors, ALK inhibitors, monoclonal antibodies, multi-targeted tyrosine kinase inhibitors, and bone-targeting agents, among others.

NEEDS ASSESSMENT

The diagnosis, risk stratification, and multi-modality state-of-the-art treatment of hematologic and solid malignancies are rapidly evolving. The development of molecular prognostic assays and novel targeted therapies provides promising tools for personalized medicine.

As a result of prior course participant evaluations and needs assessment surveys, the need for cutting edge information on prognostic markers and appropriate application of novel therapies has been identified. This year’s conference will specifically address these needs in the common malignancies identified by past participants as essential to their practice, including solid and hematologic cancers. The timing of this meeting in the fall allows for the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed. This educational activity also meets a unique need for the Northern California Sacramento Valley to provide a group of networked and collaborating oncologists a forum to discuss the most recent developments in oncology care in the context of local treatment approaches, patient populations, and open clinical trials.

The course is designed to change physician competence in oncology care. State of the art lectures and panel discussions from local and national oncologists will provide ample discussions on the applications and challenges of new prognostic tools and targeted and cytotoxic therapies. Pre-lecture and post-lecture audience response systems (evaluations) will be used in outcome measures.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclosure all relevant financial Relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
The 14th Annual Advances in Oncology program will bring together academic and community oncologists for the purpose of educating participants on the state-of-the-art developments in oncology care in the context of local treatment approaches, patient requirements, as long as the course is intended for recent advances and new diagnostic and treatment modalities in hematologic, and community oncologists. This course is intended for hematologic, and gastrointestinal cancers. The course is designed to change physician competence in oncology care.

At the conclusion of this symposium, you should be able to:

1. Discuss advances in prognostic and predictive biomarkers and potential developments in oncology care in the context of local treatment approaches, patient requirements, as long as the course is intended for recent advances and new diagnostic and treatment modalities in hematologic, and community oncologists.

2. Integrate targeted and traditional therapeutic modalities in the treatment of cancer.

3. Assess newly validated treatment options for patients with solid tumors or hematologic malignancies.

4. Develop and implement the use of modern technologies for detection, diagnosis, and treatment of cancer.

5. Discuss the role of clinical trials in advancing cancer research and treatment.

6. Analyze the ethical, legal, and social implications of advances in oncology care.

The Medical Educator Consortium designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. The course will provide ample discussions on the applications and challenges of new prognostic molecular prognostic assays and novel targeted therapies provides promising tools for personalized medicine in oncology.

The diagnosis, risk stratification, and multi-modality state-of-the-art treatment of advanced hematologic malignancies and solid tumors in defined patient populations, with emphasis on novel agents including mTOR inhibitors and other targeted therapies, will be discussed. The meeting will focus on the need for cutting edge information on prognostic markers and appropriate application of new therapies in oncology.

The AGENDA:

7:00 am - 7:30 am: Registration, continental breakfast, visit exhibits

8:30 am - 12:00 pm: Faculty Panel - “Integrating Molecular Medicine into Clinical Practice”

12:30 pm - 1:30 pm: Lunch Break

1:30 pm - 3:30 pm: Recent and Late Breaking Developments in Cancer Therapy

3:30 pm - 4:00 pm: Refreshment break, visit exhibits

4:00 pm - 6:00 pm: Practice Changing Developments in Benign and Malignant Hematology

6:00 pm - 7:30 pm: Dinner

7:30 pm - 9:30 pm: Modern Management of Advanced Kidney Cancer

9:30 pm - 11:00 pm: Challenging Cases in Breast Cancer

11:00 pm - 11:30 pm: Panel Discussion:

11:30 pm - 4:00 am: Panel:

- "Integrating Molecular Medicine into Clinical Practice"

- "Clinical Advances in Oncology: Precision Medicine with Targeted Therapies"

- "Recent and Late Breaking Developments in Cancer Therapy"

- "Practice Changing Developments in Benign and Malignant Hematology"

- "Modern Management of Advanced Kidney Cancer"

- "Challenging Cases in Breast Cancer"

- "Integrating Molecular Medicine into Clinical Practice"

- "Clinical Advances in Oncology: Precision Medicine with Targeted Therapies"

- "Recent and Late Breaking Developments in Cancer Therapy"

- "Practice Changing Developments in Benign and Malignant Hematology"

- "Modern Management of Advanced Kidney Cancer"

- "Challenging Cases in Breast Cancer"

The Lois O’Grady Lectureship: Keynote Lecture:

Scott Christensen, M.D.

"The Role of Molecular Genetics in the Diagnosis and Management of Cancer"

Edward Kim, MD, Ph.D.

Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Primo N. Lara, Jr., M.D.

Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Luko Laptalo, M.D.

Sacramento Center for Hematology/Medical Oncology
Radiological Associates of Sacramento

Tianhong Li, MD, Ph.D.

Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Gilbert L. Mandell, M.D.

Chief, Hematologist-Oncologist
Chief, Pharmacy and Therapeutics
The Permanente Medical Group
South Sacramento

Chong-xian Pan, M.D., Ph.D.

Associate Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Jonathan Riess, M.D.

Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Thomas Semrad, M.D.

Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Samer Shihabi, M.D.

Sacramento Center for Hematology/Medical Oncology
Radiological Associates of Sacramento

Joseph Tuscano, M.D.

Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Ted Wun, M.D.

Professor of Medicine
Chief, Division of Hematology and Oncology
Associate Dean for Research
UC Davis Medical Center

Alan P. Venook, M.D.

The Madden Family Distinguished Professor of Medical Oncology and Translational Research
University of California, San Francisco
San Francisco, CA

FACULTY AND PANELISTS

Kristie Bobolis, M.D.
Medical Oncologist
Capitol Hematology-Oncology

Richard Bold, M.D.
Professor of Medicine and Division Chief
Division of Surgical Oncology
UC Davis Comprehensive Cancer Center

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis School of Medicine

Scott Christensen, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

David Cooke, M.D.
Assistant Professor
Assoc. Program Director, Cardiothoracic Surgery Residency
Division of Cardiothoracic Surgery
UC Davis Medical Center

Marc Dall’Era, M.D.
Assistant Professor
Department of Urology
UC Davis Medical Center

Megan Daly, M.D.
Assistant Professor
Department of Radiation Oncology
UC Davis Comprehensive Cancer Center

Brian Druker, M.D.
Director of the Oregon Health and Science University Knight Cancer Institute
Portland, OR

David Gandara, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Tim Grennan, M.D.
Hematologist-Oncologist
Kaiser Permanente Medical Group, Morse

Richard Guy, M.D.
Hematologist-Oncologist
Kaiser Permanente Medical Group, Roseville

Kendra Hutchinson, M.D.
Associate Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Karen Kelly, M.D.
Professor of Medicine
Division of Hematology and Oncology
Associate Director for Clinical Research
UC Davis Comprehensive Cancer Center
FRIDAY, NOVEMBER 15TH
(FRIDAY ONLY at Cancer Center Auditorium UC Davis Comprehensive Cancer Center- no exhibits available on this day)

11:30 am Welcome
11:45 am Clinical Advances in Oncology: Precision Medicine with Targeted Therapies
Joseph Tuscano, M.D.
12:00 pm Introduction of Keynote Speaker: The Lois O’Grady Lectureship
Ted Wun, MD
12:10 pm O’Grady Keynote Lecture: “How Molecular Medicine Is Transforming Cancer Care”
Brian Druker, M.D.
Professor of Medicine, OHSU
Director, OHSU Knight Cancer Institute
12:55 pm Question and Answer session
1:00 pm Faculty Panel - Brian Druker, M.D., Joseph Tuscano, M.D., Ted Wun, M.D
1:15 pm Adjourn for the day

SATURDAY, NOVEMBER 16TH
(SATURDAY ONLY at the Sheraton Sacramento Hotel)

7:00 am Registration, continental breakfast, visit exhibits
8:00 am Welcome Remarks
Primo N. Lara, Jr., M.D. and Helen K. Chew, M.D.
8:05 am Pre-session Survey
Scott Christensen, M.D.
8:10 am Keynote Lecture: The Lois O’Grady Lectureship
“Integrating Molecular Medicine into Clinical Practice”
Brian Druker, M.D.
8:50 am Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings
Helen K. Chew, M.D.
9:10 am Panel Discussion: Challenging Cases in Breast Cancer
Moderator: Kendra Hutchinson, M.D.
Panel: Richard Bold, M.D., Helen Chew, M.D., Scott Christensen, M.D.,
Kristie Bobolis, M.D., Gilbert Mandell, M.D.
9:45 am Non-Small Cell Lung Cancer Therapeutics: State of the Art
David R. Gandara, M.D.
10:05 am Panel Discussion: Translating Results of Trials in Small Cell and Non-Small Cell Lung Cancer into Clinical Practice
Moderator: Jonathan Riess, M.D.
Panel: David Cooke, M.D., Megan Daly, M.D., Tianhong Li, M.D., Ph.D.,
Karen Kelly, M.D., David Gandara, M.D., Samer Shihabi, M.D.
10:35 am Refreshment break, visit exhibits
10:50 am Modern Management of Advanced Kidney Cancer
Primo N. Lara, Jr., M.D.
11:10 am Panel Discussion: Prostate and Bladder Cancer Therapy
Moderator: Primo N. Lara, Jr., M.D.
Panel: Marc Dall’era, M.D., Megan Daly, M.D., Chong-xian Pan, M.D., Ph.D.,
Luko Laptalo, M.D., Tim Grennan, M.D.
11:40 pm Practice Changing Developments in Benign and Malignant Hematology
Ted Wun, M.D.
12:00 pm Adjourn for Lunch, visit exhibits
1:00 pm Keynote Lecture: Evolving Standards of Care in Gastrointestinal Malignancies
Alan P. Venook, M.D.
1:30 pm Panel Discussion: Optimal Management of Advanced GI Cancers
Moderator: Thomas Semrad, M.D.
Panel: Alan P. Venook, M.D., Edward Kim, M.D., Richard Bold, M.D.,
Richard Guy, M.D.
2:00 pm Recent and Late Breaking Developments in Cancer Therapy
Thomas Semrad, M.D.
2:30 pm Post-session Survey/Closing Remarks: Scott Christensen, M.D.
physicians and cancer health care providers, including medical, surgical and radiation oncologists for the purpose of educating participants on the state-of-the-art in cancer treatment. The extent of their participation in the activity.

The Medical Educator Consortium designates this live activity for a maximum of 7.0 PRA Category 1 Credit(s)™

The diagnosis, risk stratification, and multi-modality state-of-the-art treatment of novel therapies has been identified. This year’s conference will specifically address the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed. This educational activity also meets a unique need for the Northern California Sacramento Valley to provide a wide range of targeted and cytotoxic therapies. Pre-lecture and post-lecture audience tools and targeted and cytotoxic therapies provides promising tools of novel therapies has been identified. This year’s conference will specifically address molecular prognostic assays and novel targeted therapies.

NEEDS ASSESSMENT

1. Discuss advances in prognostic and predictive biomarkers and potential inhibitors, and bone-targeting agents, among others.

2. Apply data from recent clinical trials to determine the optimal course of therapy taken within the appropriate time frames.


4. Apply data from recent clinical trials to determine the optimal course of therapy taken within the appropriate time frames.

PANELISTS

- **Translational Research**
  - Brian Druker, M.D.
  - Edward Kim, M.D., Ph.D.

- **Challenging Cases in Breast Cancer**
  - Scott Christensen, M.D.

- **Evolving Standards of Care in Gastrointestinal Malignancies**
  - Primo N. Lara, Jr., M.D.
  - Jonathan Riess, M.D.

- **Clinical Advances in Oncology: Precision Medicine with Targeted Therapies**
  - Edward Kim, M.D., Ph.D.

- **Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings**
  - Kristie Bobolis, M.D., Gilbert Mandell, M.D.

- **Non-Small Cell Lung Cancer Therapeutics: State of the Art**
  - Jonathan Riess, M.D.

- **Practice Changing Development in Benign and Malignant Hematology**
  - Megan Daly, M.D.

AGENDA

- 8:10 a.m. Welcome Remarks
  - Brian Druker, M.D.

- 8:15 a.m. AGENDA PANEL: Introduction of Keynote Speaker:
  - Brian Druker, M.D.

- 8:40 a.m. O’Grady Keynote Lecture:
  - Introduction
  - Brian Druker, M.D.

- 9:00 a.m. AGENDA PANEL: Evolving Standards of Care in Gastrointestinal Malignancies
  - Primo N. Lara, Jr., M.D.
  - Jonathan Riess, M.D.

- 10:00 a.m. AGENDA PANEL: Challenging Cases in Breast Cancer
  - Scott Christensen, M.D.

- 11:00 a.m. AGENDA PANEL: Clinical Advances in Oncology: Precision Medicine with Targeted Therapies
  - Edward Kim, M.D., Ph.D.

- 12:00 p.m. AGENDA PANEL: Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings
  - Kristie Bobolis, M.D., Gilbert Mandell, M.D.

- 1:00 p.m. AGENDA PANEL: Non-Small Cell Lung Cancer Therapeutics: State of the Art
  - Jonathan Riess, M.D.

- 2:00 p.m. AGENDA PANEL: Practice Changing Development in Benign and Malignant Hematology
  - Megan Daly, M.D.

- 3:00 p.m. AGENDA PANEL: Evolving Standards of Care in Gastrointestinal Malignancies
  - Primo N. Lara, Jr., M.D.
  - Jonathan Riess, M.D.

- 4:00 p.m. AGENDA PANEL: Challenging Cases in Breast Cancer
  - Scott Christensen, M.D.

- 5:00 p.m. AGENDA PANEL: Clinical Advances in Oncology: Precision Medicine with Targeted Therapies
  - Edward Kim, M.D., Ph.D.

- 6:00 p.m. AGENDA PANEL: Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings
  - Kristie Bobolis, M.D., Gilbert Mandell, M.D.

- 7:00 p.m. AGENDA PANEL: Non-Small Cell Lung Cancer Therapeutics: State of the Art
  - Jonathan Riess, M.D.

- 8:00 p.m. AGENDA PANEL: Practice Changing Development in Benign and Malignant Hematology
  - Megan Daly, M.D.

For more information contact:

MECC 1550 S Dixie Highway Suite 202, Coral Gables, FL 33146
Telephone 305/663-1628 Office Fax 305/675-2718
Or visit our website at www.meccinc.com
Email: tvalls@meccinc.com
Register online at www.meccinc.com or FAX to 305/675-2718.

Name _____________________________________________ Degree __________________
__________________________________________________________________________
City _________________________________ State ___________________ Zip ___________
(____)___________________________ FAX (____)________________________
Email address _______________________________________________________________
Specialty ___________________________________________________________________

Type of Practice:
q Private
q Academic
q Hospital
q Resident/Fellow

I will be attending
q BOTH days November 15 and 16
q ONLY Friday November 15 at the Cancer Center Auditorium
q ONLY Saturday, November 16 at the Sheraton Sacramento

Registration fee
$150 Physicians
$75 Nurses, Fellows, Residents and Allied Health Care
$250 Industry Professionals

Refunds must be provided in writing prior to October 16, 2013. After October 16, 2013, No Refunds will be provided.

Enclosed is my check i/a/o of _____ for registration of this course.

I authorize MECC to charge my credit card i/a/o $_______ for registration of this

CONFERENCE LOCATION
This conference is held at two locations. No transportation will be provided from the
host hotel.

Parking is available in the lot adjacent to the Cancer Center.

For more information contact:
CONFERENCE MANAGEMENT
MEC 1550 S Dixie Highway Suite 202, Coral Gables, FL  33146
Telephone 305/663-1628 Office Fax 305/675-2718
Or visit our website at www.meccinc.com

CONFERENCE DIRECTORS
Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

Primo N. Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

PRESENTED BY
UC DAVIS
COMPREHENSIVE
CANCER CENTER

SPONSORED BY:
THE MEDICAL EDUCATOR
CONSORTIUM
COMPREHENSIVE
CANCER  CENTER

14th Annual Advances in Oncology 2013
SHERATON SACRAMENTO
1220 J Street
Sacramento, CA 95814